Day One Biopharmaceuticals, Inc. Profile

Industry

Biotechnology

Sector

Healthcare

Number of Employees

155

Day One Biopharmaceuticals's Business Model

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

About Day One Biopharmaceuticals

Website: https://dayonebio.com

CEO (Chief Executive Officer): Dr. Jeremy Bender M.B.A., Ph.D.

IPO date: 2021-05-27

Contact

Country: US

Address: 395 Oyster Point Boulevard

City: South San Francisco

State: CA

Phone: 650 484 0899

Zip Code: 94080

Other

CIK: 0001845337

ISIN: US23954D1090

CUSIP: 23954D109

Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.